Amedisys Q2 2025 Financial Results

Amedisys, Inc. reported its financial results for the second quarter of 2025, showing a 5% increase in revenue to $621.9 million compared to $591.2 million in the same period last year. Net income attributable to Amedisys, Inc. was $28.1 million, down from $32.3 million in 2024, primarily due to higher merger-related expenses. Adjusted EBITDA increased to $80.8 million from $73.2 million in 2024. The company also reported growth in key metrics, including a 29% increase in total admissions and a 6% rise in same-store home health admissions. Amedisys highlighted its strong cash flow from operations, which stood at $67.2 million, and a net leverage ratio of 0.1x. The company did not conduct an earnings call due to its pending merger with UnitedHealth Group.